james smith
02-15-2008, 02:30 AM
indoleamine-pyrrole 2,3 dioxygenase
Indoleamine-pyrrole 2,3 dioxygenase (IDO) catalyzes the conversion of tryptophan to N-formylkynurenine, the first and rate-limiting step of tryptophan catabolism through the kynurenine pathway. Over expressed in tumour cells, IDO enables cancer cells to escape immune response, as depleted tryptophan levels sensitize activated T cells to apoptosis. Reduced tryptophan levels also halt microbe growth.
NewLink Genetics is developing NLG-001, a small molecule IDO inhibitor for the treatment of cancer.
IDO belongs to the Enzyme > Oxygenase Target Family Group and its EC number is 1.13.11.52. Its Entrez Gene ID is 3620.
peptidylprolyl isomerase B (cyclophilin B)
Sometimes referred to as CYPB or PPIB, this enzyme is predominantly located in the endoplasmic reticulum. Interactions with HIV-1 gp120 and Pr55gag as well as stimulation of the RNA binding activity of the Hepatitis C RNA polymerase NS5B have been reported.
Scynexis is developing SCY-635, a CYPB inhibitor for the treatment of HCV and HIV infection.
CYPB belongs to the Enzyme > Isomerase Target Family Group and its EC number is 5.2.1.8. Its Entrez Gene ID is 5479.
for more info, visit:
http://www.pharmaprojects.com/new_drug_targets/ndt_0108.htm#Indoleamine
Indoleamine-pyrrole 2,3 dioxygenase (IDO) catalyzes the conversion of tryptophan to N-formylkynurenine, the first and rate-limiting step of tryptophan catabolism through the kynurenine pathway. Over expressed in tumour cells, IDO enables cancer cells to escape immune response, as depleted tryptophan levels sensitize activated T cells to apoptosis. Reduced tryptophan levels also halt microbe growth.
NewLink Genetics is developing NLG-001, a small molecule IDO inhibitor for the treatment of cancer.
IDO belongs to the Enzyme > Oxygenase Target Family Group and its EC number is 1.13.11.52. Its Entrez Gene ID is 3620.
peptidylprolyl isomerase B (cyclophilin B)
Sometimes referred to as CYPB or PPIB, this enzyme is predominantly located in the endoplasmic reticulum. Interactions with HIV-1 gp120 and Pr55gag as well as stimulation of the RNA binding activity of the Hepatitis C RNA polymerase NS5B have been reported.
Scynexis is developing SCY-635, a CYPB inhibitor for the treatment of HCV and HIV infection.
CYPB belongs to the Enzyme > Isomerase Target Family Group and its EC number is 5.2.1.8. Its Entrez Gene ID is 5479.
for more info, visit:
http://www.pharmaprojects.com/new_drug_targets/ndt_0108.htm#Indoleamine